Pharma: After failed Reppegather deals: Bafin finds accounting errors at Dermapharm
The financial supervisory authority has identified two errors in the 2025 consolidated financial statements. This raises new questions about the pharmaceutical company's dealings with the Reppegather brothers.
We haven't written up this one. Handelsblatt has the full story — the link below goes straight to it.